ReviewSmall (Weinheim an der Bergstrasse, Germany)2026
Precision-Engineered PROTACs: Integrating Physical and Chemical Strategies for Targeted Cancer Therapy.
Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Proteolysis-targeting chimeras (PROTACs) have emerged as a transformative therapeutic strategy for targeted protein degradation, offering substantial potential for treating various diseases by specifically eliminating pathogenic proteins. However, the clinical translation of PROTAC technology faces significant challenges due to limited target selectivity, which may lead to off-target effects and potential toxicity in healthy tissues. Recent advances have focused on developing conditionally activatable PROTAC systems to improve their specificity and safety profile. This review comprehensively examines two primary classes of engineered PROTACs: (i) physically regulated systems, including photo-activatable, radiation, and ultrasound-activatable platforms, and (ii) chemically controlled approaches employing bioorthogonal conjugation strategies. We systematically analyze their molecular mechanisms, current clinical applications in oncology, and existing limitations regarding therapeutic efficacy and safety. The development of these precisely controlled PROTAC platforms promises to significantly enhance the clinical utility of targeted protein degradation technology in modern drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.